var quiz = [
  {
    q: `<!--1. -->The immune system has two basic arms, designated “innate” and adaptive. Regarding these divisions, which of the following is true?`,
    q2: ``,
    q3: [],
    option: [
      `<!--a. -->The adaptive immune system is the more primitive of the two.`,
      `<!--b. -->The innate immune system includes long-lived “memory” cells that make secondary responses to pathogens more rapid and stronger.`,
      `<!--c. -->The adaptive immune system is the only part of the immune system involved in the immune response to cancer.`,
      `<!--d. -->The innate immune response is driven by recognition of repeated patterns in pathogens called pathogen associated molecular patterns (PAMPs).`,
    ],
    optionStyleType: `st-lower-alpha`,
    answer: [3],
    ansText: `Rationale:  <b>The innate system is more primitive and does not contain cell types that can give rise to memory cells.</b> In most immune responses, the innate and adaptive systems work together.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },
  {
    q: `<!--2. -->Immunotherapy for non–muscle-invasive bladder cancer is based on intravesical administration of bacillus Calmette-Guérin (BCG). Initial contact between BCG and the immune system involves which cell type?`,
    q2: ``,
    q3: [],
    option: [
      `<!--a. -->Neutrophils, also known as polymorphonuclear cells (PMNs)`,
      `<!--b. -->CD4+ (helper) T cells`,
      `<!--c. -->Macrophages (“Big eaters”)`,
      `<!--d. -->CD8+ (killer) T cells`,
      `<!--e. -->CD8+ regulatory T cells (Tregs)`,
    ],
    optionStyleType: `st-lower-alpha`,
    answer: [1],
    ansText: `Rationale: Although BCG does bind directly to bladder epithelium, the first immune cell involved in BCG responses is the macrophage (“big eater”).`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },
  {
    q: `<!--3. -->Macrophages and neutrophils have the following feature(s) in common:`,
    q2: ``,
    q3: [],
    option: [
      `<!--a. -->they can both ingest pathogens.`,
      `<!--b. -->they can both present peptide antigens from pathogens on major histocompatibility complex (MHC) class II molecules.`,
      `<!--c. -->they can both kill pathogens via oxidative processes.`,
      `<!--d. -->they can both migrate along chemokine gradients to sites of infection.`,
      `<!--e. -->c and d.`,
    ],
    optionStyleType: `st-lower-alpha`,
    answer: [4],
    ansText: `Rationale: <b>Macrophages and PMNs are both innate immune cells involved in the early phases of an immune response.</b> Although both have potent cytotoxic activity, only macrophages can ingest pathogens and present antigens in the context of MHC molecules.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },
  {
    q: `<!--4. -->Cytokines are chemical messengers that direct immune cell migration and differentiation. Which of the following is true regarding cytokines?`,
    q2: ``,
    q3: [],
    option: [
      `<!--a. -->Interleukin 8 (IL-8) is a Th1 cytokine that helps naive CD4+ T cells differentiate into cells that secrete IL-4.`,
      `<!--b. -->Interferon α is an adaptive cytokine that has no role in the response to BCG.`,
      `<!--c. -->Interferon γ is an innate cytokine mostly secreted by luminal epithelial cells in the bladder.`,
      `<!--d. -->Th1 cytokines include IL-4, IL-5, and IL-10.`,
      `<!--e. -->The primary Th1 cytokine is IL-12.`,
    ],
    optionStyleType: `st-lower-alpha`,
    answer: [4],
    ansText: `Rationale: <b>Th1 responses are characterized by IL-12, interferon</b> γ <b>(not</b> α<b>) and tumor necrosis factor (TNF)</b> α<b>.</b> Th1 responses are involved in viral clearance and in antitumor immune responses. Th2 responses (IL4, 5, 10, and 13) are associated with chronic inflammation and infection and generally prevent an antitumor immune response. In bladder cancer, Th2 cytokines in the urine after BCG treatment portend a generally worse outcome.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },
  {
    q: `<!--5. -->The most important adaptive immune cells are B and T cells. Which of the following is true?`,
    q2: ``,
    q3: [],
    option: [
      `<!--a. -->B cells are called B cells because they come from the bone marrow.`,
      `<!--b. -->CD4 (helper) T cells are mostly of a single phenotype.`,
      `<!--c. -->CD8 T cells are specialized for cytotoxicity; they evolved to destroy virally infected cells.`,
      `<!--d. -->Regulatory T cells (Tregs) are a subset of CD8 T cells.`,
      `<!--e. -->In non–muscle-invasive bladder cancer, a Th2 response involving IL-4, IL-5, and IL-10 is associated with a better outcome.`,
    ],
    optionStyleType: `st-lower-alpha`,
    answer: [2],
    ansText: `Rationale: <b>CD4 T cells are complex and include a number of phenotypes (Th1, Th2, Tregs, and others).</b> CD8 T cells are cytotoxic and are capable of killing nearly any target cell (including cells resistant to chemotherapy). Although B cells DO come from the bone marrow, that is not how they got their name. They were discovered in chickens in an organ called the bursa of Fabricius. The B comes from the word <b><i>bursa.</i></b>`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },
  {
    q: `<!--6. -->The major function of B cells is to:`,
    q2: ``,
    q3: [],
    option: [
      `<!--a. -->kill bacterially infected cells.`,
      `<!--b. -->generate antibodies which help macrophages to phagocytose and destroy pathogens.`,
      `<!--c. -->differentiate into memory cells that provide a secondary immune response about equal in magnitude to a primary response.`,
      `<!--d. -->ingest pathogens.`,
      `<!--e. -->augment the function of BCG by generating anti-BCG antibodies that lead to BCG persistence in the bladder.`,
    ],
    optionStyleType: `st-lower-alpha`,
    answer: [1],
    ansText: `Rationale: <b>B cells secrete antibodies, which help to clear pathogens.</b> They also differentiate into memory B cells, which drive a stronger and faster secondary response on reexposure to a pathogen. The generation of antibodies to BCG is probably a negative event; it would be expected to lead to a faster clearance and a less robust antitumor effect.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },
  {
    q: `<!--7. -->CD4 T cell subsets include:`,
    q2: ``,
    q3: [],
    option: [
      `<!--a. -->Tregs that augment an antitumor immune response.`,
      `<!--b. -->Th1 T cells that secrete IL-1.`,
      `<!--c. -->Th2 T cells that secrete IL-4, IL-5, IL-10, and IL-13.`,
      `<!--d. -->Th9 T cells that are involved in CD8 T-cell killing.`,
      `<!--e. -->Th8 T cells that have a cytotoxic function.`,
    ],
    optionStyleType: `st-lower-alpha`,
    answer: [2],
    ansText: `Rationale: <b>As earlier, Th2 cells secrete IL4, 5, 10, and 13, all of which generally inhibit a successful antitumor response.</b>`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },
  {
    q: `<!--8. -->The immune editing hypothesis explains how tumors evolve in an immunologically competent host. The three E’s in the immune editing hypothesis (in order) include:`,
    q2: ``,
    q3: [],
    option: [
      `<!--a. -->elimination, equilibrium, and escape.`,
      `<!--b. -->escape, equilibrium, and elimination.`,
      `<!--c. -->elucidation, escape, and election.`,
      `<!--d. -->evolution, equilibrium, and elimination.`,
    ],
    optionStyleType: `st-lower-alpha`,
    answer: [0],
    ansText: `Rationale: <!--<b>a. Elimination, equilibrium and escape.</b>--> <b>See text for explanation.</b>`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },
  {
    q: `<!--9. -->There is a clear epidemiologic link between chronic inflammation and certain genitourinary (GU) cancers. Which of the following best describes this relationship?`,
    q2: ``,
    q3: [],
    option: [
      `<!--a. -->Correlative data are strongest in kidney cancer, where chronic inflammation leads to clear cell cancer or renal cell carcinoma.`,
      `<!--b. -->Data for this link are absent in prostate cancer.`,
      `<!--c. -->In bladder cancer, chronic infection with <i>Schistosoma haematobium</i> (schistosomiasis) rarely leads to cancer with a squamous cell phenotype.`,
      `<!--d. -->In prostate cancer, inflammation has been associated with the consumption of charred meat and its associated toxins.`,
    ],
    optionStyleType: `st-lower-alpha`,
    answer: [3],
    ansText: `Rationale: <b>In GU cancers, the strongest linkage between chronic inflammation and tumorigenesis is in bladder cancer, where chronic infection with schistosomiasis leads to squamous cell cancers.</b> There are also strong data in prostate cancer, although the precise etiology of prostatic inflammation has yet to be fully defined.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },
  {
    q: `<!--10. -->The presence of CD8 T cells is associated with:`,
    q2: ``,
    q3: [],
    option: [
      `<!--a. -->a better prognosis in all GU tumor types, since CD8 T cells are cancer-fighting cytotoxic cells.`,
      `<!--b. -->a better prognosis in bladder cancer and prostate cancer.`,
      `<!--c. -->A worse prognosis in kidney cancer.`,
      `<!--d. -->A better prognosis in prostate cancer. This is well documented, since prostate tumors are frequently highly infiltrated with CD8 T cells.`,
    ],
    optionStyleType: `st-lower-alpha`,
    answer: [2],
    ansText: `Rationale: <b>Although cytotoxic CD8 T cells are generally associated with a better prognosis, in kidney cancer the opposite relationship has been described.</b> This is a puzzling finding, which is not well understood. In bladder cancer, a robust CD8 infiltrate is generally associated with an improved outcome.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },
  {
    q: `<!--11. -->Immune checkpoint molecules are:`,
    q2: ``,
    q3: [],
    option: [
      `<!--a. -->a series of intracellular proteins that regulate progression of T cells through the cell cycle.`,
      `<!--b. -->a series of extracellular proteins that promote T-cell activation and effector function.`,
      `<!--c. -->a series of proteins on innate immune cells that inhibit their function.`,
      `<!--d. -->a series of cell-surface proteins that attenuate CD8 T-cell effector function when bound to their specific cognate ligands.`,
    ],
    optionStyleType: `st-lower-alpha`,
    answer: [3],
    ansText: `Rationale: <b>Immune checkpoint molecules are cell-surface proteins that attenuate CD8 T cell function.</b>`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },
  {
    q: `<!--12. -->In non–muscle-invasive bladder cancer (NMIBC), the immunotherapeutic effects of BGC are mediated by all of the following EXCEPT which?`,
    q2: ``,
    q3: [],
    option: [
      `<!--a. -->The innate immune system, mostly through the activation of neutrophils and macrophages`,
      `<!--b. -->The release of chemokines from luminal epithelial cells in the bladder`,
      `<!--c. -->CD4 T cells of the Th2 phenotype`,
      `<!--d. -->CD8 T cells of the Tc1 phenotype that participate in the direct killing of tumor cells`,
    ],
    optionStyleType: `st-lower-alpha`,
    answer: [2],
    ansText: `Rationale: <b>As earlier, Th2 CD4 T cells are associated with a worse outcome in bladder cancer.</b>`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },
  {
    q: `<!--13. -->Cancer vaccines are intended to raise an adaptive immune response to a target antigen expressed preferentially on tumor cells. Which of the following is a US Food and Drug Administration (FDA)–approved vaccine for a GU cancer type?`,
    q2: ``,
    q3: [],
    option: [
      `<!--a. -->ProstVac VF, which is used in prostate cancer`,
      `<!--b. -->IMA901, a multi-peptide vaccine for kidney cancer`,
      `<!--c. -->Gardasil, a vaccine against human papillomavirus`,
      `<!--d. -->Sipuleucel-T, a prostatic acid phosphatase (PAP)–directed vaccine for prostate cancer`,
    ],
    optionStyleType: `st-lower-alpha`,
    answer: [3],
    ansText: `Rationale: <b>Although many cancer vaccines have been tested in GU cancers, only Sipuleucel-T is approved.</b> This vaccine targets the antigen PAP in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },
  {
    q: `<!--14. -->The interaction between the immune checkpoint molecule PD-1 (on CD8 T cells) and its ligand PD-L1 (on tumor cells) does which of the following?`,
    q2: ``,
    q3: [],
    option: [
      `<!--a. -->Helps CD8 T cells to activate dendritic cells`,
      `<!--b. -->Drives CD8 T cells to secrete interferon γ, promoting antitumor responses`,
      `<!--c. -->Mediates an “exhausted” nonfunctional phenotype in the CD8 T cells that express PD-1`,
      `<!--d. -->Signals through PD-L1 back into the tumor cell to promote tumor cell destruction`,
    ],
    optionStyleType: `st-lower-alpha`,
    answer: [2],
    ansText: `Rationale: <b>Expression of PD-1 on tumor-infiltrating CD8 T cells is associated with a nonfunctional, exhausted phenotype.</b> Blockage of the PD-1/PD-L1 interaction with monoclonal antibodies restores CD8 T-cell function, leading to tumor destruction (and shrinkage) in a minority of treated patients.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },
  {
    q: `<!--15. -->In bladder cancer, blockage of the interaction between PD-1 and PD-L1 using monoclonal antibodies:`,
    q2: ``,
    q3: [],
    option: [
      `<!--a. -->provides a survival benefit but only when used with chemotherapy.`,
      `<!--b. -->improves both progression-free and overall survival as compared with second-line chemotherapy.`,
      `<!--c. -->improves survival but leads to tumor response (shrinkage) in less than 10% of treated patients.`,
      `<!--d. -->signals through PD-L1 back into the tumor cell to promote tumor cell destruction.`,
      `<!--e. -->frequently leads to complete responses.`,
    ],
    optionStyleType: `st-lower-alpha`,
    answer: [1],
    ansText: `Rationale: <b>Blockage of either PD-1 or PD-L1 is effective in bladder cancer in the second-line setting (as compared with chemotherapy).</b> The overall response rate to these agents is in the range of 20% to 25%.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },
  {
    q: `<!--16. -->PD-1 is not the only immune checkpoint molecule expressed on T cells in tumors; other checkpoint molecules include CTLA-4, LAG-4, and others. Simultaneously blocking <i>two</i> immune checkpoints (PD-1 and CTLA-4) in first-line kidney cancer:`,
    q2: ``,
    q3: [],
    option: [
      `<!--a. -->is less toxic than blocking a single immune checkpoint molecule.`,
      `<!--b. -->is more effective than first-line therapy with a vascular endothelial growth factor (VEGF) TKI (a tyrosine kinase inhibitor).`,
      `<!--c. -->never leads to complete responses.`,
      `most likely functions by blocking both molecules on the same cell type.`,
      `<!--e. -->rarely leads to autoimmunity in endocrine organs.`,
    ],
    optionStyleType: `st-lower-alpha`,
    answer: [1],
    ansText: `Rationale: <b>Combined immune checkpoint blockade with anti-PD-1 (nivolumab) and anti-CTLA-4 (ipilimumab) is an approved first-line therapy for clear-cell RCC.</b> It is more effective than treatment with the TKI sunitinib, as evidence by improved overall survival and progression-free survival. However, it is also considerably more toxic, with endocrine-related adverse events being reasonably common.`,
    state: `notAnswered`,
    userAnswered: [],
    type: `MCSS`,
  },
];
